WO2018155660A1 - Composition comprenant des cellules mortes de bactéries d'acide lactique ou une substance traitée de celles-ci, et article cosmétique, produit de consommation courante, médicament ainsi qu'aliment contenant cette composition - Google Patents

Composition comprenant des cellules mortes de bactéries d'acide lactique ou une substance traitée de celles-ci, et article cosmétique, produit de consommation courante, médicament ainsi qu'aliment contenant cette composition Download PDF

Info

Publication number
WO2018155660A1
WO2018155660A1 PCT/JP2018/006832 JP2018006832W WO2018155660A1 WO 2018155660 A1 WO2018155660 A1 WO 2018155660A1 JP 2018006832 W JP2018006832 W JP 2018006832W WO 2018155660 A1 WO2018155660 A1 WO 2018155660A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
composition
lactic acid
improving
skin
Prior art date
Application number
PCT/JP2018/006832
Other languages
English (en)
Japanese (ja)
Inventor
啓子 北村
逸志 樫本
Original Assignee
Ｒａｐａｓ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ｒａｐａｓ株式会社 filed Critical Ｒａｐａｓ株式会社
Priority to JP2019501847A priority Critical patent/JPWO2018155660A1/ja
Publication of WO2018155660A1 publication Critical patent/WO2018155660A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair

Definitions

  • the present invention relates to a composition containing dead cells of lactic acid bacteria or a processed product thereof, and cosmetics, daily necessities, drugs or foods containing the composition.
  • Dead lactic acid bacteria (bactericidal cells) have a different mechanism of action in vivo than live bacteria and lactic acid bacteria-producing substances, and induce immune activity by being taken into Bayer plates in the intestinal tract. . Specifically, it is said that dead cells of lactic acid bacteria taken up by immune tissues are recognized by antigen-presenting cells, promote production of transmitters such as cytokines, and act on immune equivalent cells to regulate immunity.
  • lactic acid bacteria-derived dead cells are known as arteriosclerosis, hyperlipidemia, serum cholesterol lowering, cancer prevention, antitumor effect, immune function factory, liver function, adult disease prevention and the like. However, it is not clear what effect lactic acid bacteria-derived dead cells have.
  • Patent Document 1 discloses a “livestock / poultry or fishery product infection control agent characterized by containing dead lactic acid bacteria or a processed product thereof and chitosan as active ingredients”.
  • Patent Document 2 has “lactic acid bacteria nanoparticles having a primary particle peak particle size of 1 ⁇ m or less in a frequency distribution containing lactic acid bacteria consisting of dead bacteria of lactic acid bacteria, and is absorbed into the body from the oral mucosa.
  • An immune function-regulating oral preparation characterized by adjusting the immune function.
  • Patent Document 3 discloses a “body fat accumulation inhibitor containing lactic acid bacteria killed as an active ingredient”. The above patent documents do not disclose or suggest the use of the composition of the present invention.
  • the present inventors have found a new use of dead cells of lactic acid bacteria by selecting an optimal lactic acid bacterium and further selecting an optimal additive, and completed the present invention. did. That is, the present invention is as follows. 1. A composition having one or more of the following uses, characterized by containing natto bacteria, dead lactic acid bacteria, or a processed product thereof. (1) For improving skin tension (2) For improving spots (3) For improving wrinkles (4) For improving dullness (5) For reducing and / or tightening pores (6) For acne and / or pimples For improvement 2. The composition according to item 1, wherein the lactic acid bacterium is Enterococcus faecalis. 3. 2.
  • composition according to item 1, wherein the lactic acid bacterium is Enterococcus faecium. 4). 4. The composition according to any one of items 1 to 3, wherein the use is for improving skin tension. 5). 4. The composition according to any one of items 1 to 3, wherein the use is for improving spots. 6). 4. The composition according to any one of items 1 to 3, wherein the use is for improving wrinkles. 7). 4. The composition according to any one of items 1 to 3, wherein the use is for improving dullness. 8). 4. The composition according to any one of items 1 to 3, wherein the use is pore reduction and / or tightening. 9. 4. The composition according to any one of items 1 to 3, wherein the use is for improving acne and / or breakout. 10. 10.
  • a cosmetic comprising the composition according to any one of 1 to 10 above.
  • 12 A composition having one or more of the following uses, which contains dead lactic acid bacteria or a treated product thereof. (1) For improving skin (2) For increasing moisture content in skin (3) For reducing skin age (4) For improving hair quality (5) For reducing stomatitis (6) For reducing periodontal disease (7) 12. For bad breath reduction (8) Burn recovery promotion (9) Skin itch reduction (10) Constipation improvement (11) Diarrhea improvement 13.
  • composition according to item 12 above, wherein the lactic acid bacterium is Enterococcus faecium. 15.
  • the composition according to any one of items 12 to 16, wherein the use is for skin improvement. 18.
  • the composition according to any one of items 12 to 16, wherein the use is for increasing the moisture content of skin. 19.
  • the composition according to any one of items 12 to 16, wherein the use is for reducing skin age. 20.
  • composition according to any one of items 12 to 16, wherein the use is for reducing stomatitis. 22. 17.
  • the composition according to any one of items 12 to 16, wherein the use is for reducing periodontal disease. 23. 17.
  • the composition according to any one of items 12 to 16, wherein the use is for reducing bad breath. 24.
  • the composition according to any one of items 12 to 16, wherein the use is for promoting burn recovery. 25.
  • the composition according to any one of items 12 to 16, wherein the use is for reducing skin itchiness. 26. 17.
  • the composition according to any one of items 12 to 16, wherein the use is for improving constipation. 27. 17.
  • the composition according to any one of items 12 to 16, wherein the use is for diarrhea improvement. 28. 28.
  • composition according to any one of items 12 to 27, wherein the composition is a cosmetic additive composition. 29. 28.
  • 30. 28. The composition according to any one of items 12 to 27, wherein the composition is a composition for drug addition.
  • a cosmetic comprising the composition according to any one of items 12 to 27 above.
  • 28. A consumer product comprising the composition according to any one of items 12 to 27 above.
  • a drug comprising the composition according to any one of 12 to 27 above. 34.
  • the composition containing dead cells of lactic acid bacteria (particularly Enterococcus faecalis, Enterococcus faecium) of the present invention or a processed product thereof has one or more of the following effects.
  • (1) Improvement of skin tension (2) Improvement of spots (3) Improvement of wrinkles (4) Improvement of dullness (5) Reduction and / or tightening of pores (6) Improvement of acne and / or pimples (7)
  • Skin (8) Increase of skin moisture (9) Reduction of skin age (10) Improvement of hair quality (11) Reduction of stomatitis (12) Reduction of periodontal disease (13) Reduction of bad breath (14) Promotion of burn recovery (15 ) Reduction of skin itching (16) Improvement of constipation (17) Improvement of diarrhea (18) Improvement of body odor (19) Improvement of halitosis (20) Stabilization (21) Improvement of allergy and / or atopy (22) Improvement of diarrhea, improvement of constipation and / Or bowel improvement (23) lower stomach circumference
  • the present invention relates to “a composition containing a dead cell of lactic acid bacteria or a processed product thereof” and “a cosmetic, a daily product, a drug or a food comprising a dead cell of lactic acid bacteria or a processed product thereof”. Details will be described below.
  • the “dead cells of lactic acid bacteria” used in the present invention are not particularly limited as long as they are not so-called live bacteria.
  • methods for treating dead lactic acid bacteria include heating, ultraviolet irradiation, formalin treatment, and the like.
  • the cultured lactic acid bacteria can be obtained by repeating washing and dehydration a plurality of times as necessary, suspending in water or the like, and heating the suspension.
  • the processed product of dead microbial cells of the lactic acid bacterium according to the present invention includes various treatments (washing, far-dehydration, heating, gamma ray or neutron irradiation, spray drying, freeze drying, sterilization, Enzymes, surfactants, grinding, grinding, etc.).
  • “Sterilization” may include a step of removing cells by filtration or the like. That is, the treated product of dead cells of lactic acid bacteria according to the present invention is obtained from a fermentation liquid (culture solution) obtained by fermenting a substrate (eg, animal substances such as milk and plant substances such as fruit juice) with lactic acid bacteria. Body and / or dead cells).
  • a substrate eg, animal substances such as milk and plant substances such as fruit juice
  • known methods can be used, and examples include spray drying and freeze drying.
  • Lactic acid bacteria used in the present invention are intended for lactic acid bacteria in a broad sense.
  • lactic acid bacteria are defined as bacteria that produce lactic acid by metabolism. Lactic acid bacteria are characterized by their morphology, fermentation products, etc., and can be classified into Lactobacillus genus, Bifidobacterium genus, Enterococcus genus, Lactococcus genus, Pediococcus genus, Leuconocus genus. It is classified into the genus of stock (Leuconostoc). Each genus includes various species such as casei, brevis, and johnsonii.
  • lactobacilli for example, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus salivarius, Lactobacillus brevis, Lactobacillus plantarum, Lactobacillus helveticus, Lactobacillus fermentum, Lactobacillus paracasei, Lactobacillus casei, Lactobasi Keys, Lactobacillus reuteri, Lactobacillus johnsonii, Lactobacillus gasseri, Lactobacillus kefir, Lactobacillus brunerii etc.
  • lactobacilli for example, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus salivarius, Lactobacillus brevis, Lactobacillus plantarum, Lactobacillus helveticus, Lactobacillus fermentum, Lactobacillus paracasei, Lactobacillus casei, Lactobasi Keys, Lactobacillus re
  • Lactococci examples include, for example, Enterococcus faecium, Enterococcus faecalis, Lactococcus lactis, Lactococcus plantarum, Lactococcus raffinolactis, Streptococcus thermophilus, Leuconostoc lactis, Leuconostoc mecenteloides be able to.
  • Bifidobacterium examples include Bifidobacterium infantis, Bifidobacterium breve, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium pseudoron Examples include gum, Bifidobacterium thermophilum, Bifidobacterium adrecentis and the like.
  • lactic acid bacteria can be used in combination with one or more bacterial species.
  • These lactic acid bacteria can be obtained by culturing under arbitrary conditions according to a conventional method of lactic acid bacteria culture.
  • Particularly preferred lactic acid bacteria are Enterococcus faecalis, Enterococcus faecium, Bifidobacterium longum, Lactobacillus casei subspecies casei, Lactobacillus paracasei and Lactobacillus crispatus.
  • These lactic acid bacteria can be obtained from a commercial product or an organization that distributes these bacteria.
  • the lactic acid bacteria according to the present invention are not limited to the above strains, and can be used as long as they belong to the lactic acid bacteria and have one or more effects of the present invention. That is, mutants and progeny that are strains having the above-mentioned mycological properties are intended.
  • the mutant preparation method can be obtained by conventionally known irradiation and chemical substance treatment such as nitrosoguanidine, ethylmethanesulfonic acid, methylmethanesulfonic acid and the like.
  • the lactic acid bacteria according to the present invention are not toxic even when administered in vivo (particularly in the body) as shown in the following examples.
  • the lactic acid bacterium according to the present invention is inoculated into a nutrient medium containing a carbon source and a nitrogen source and, if necessary, an inorganic salt, and then cultured under aerobic conditions (for example, shaking culture, aeration and agitation culture), Can be obtained.
  • the non-concentrated culture solution has the same activity even after the filter sterilized culture solution or after freeze-drying or spray-drying thereof.
  • the fruit is obtained by using the solid itself or a mixture thereof (for example, a contact or mixture with another solid or a liquid in which the lactic acid bacteria growth solid according to the present invention is immersed). Can have.
  • the solid may be any material as long as the lactic acid bacterium according to the present invention can grow.
  • the solid means plants that are raw materials such as agar medium, silage, natto, and milk curd represented by yogurt.
  • Any carbon source may be used as long as the lactic acid bacteria according to the present invention can be used.
  • Glucose, sucrose, starches, cellulose mixtures, and other carbohydrates are preferably used.
  • Any nitrogen source may be used as long as the lactic acid bacteria according to the present invention can be used, but preferably, peptone, yeast extract, gravy extract, or the like is used.
  • inorganic salts such as sodium salt, potassium salt, magnesium salt, calcium salt, sulfate, phosphate and the like may be added to the medium.
  • the lactic acid bacteria according to the present invention can grow in liquid or plate cultures inoculated on commercially available media such as tryptosoy media, brain heart infusion media, and gravy media. When culturing in a small amount in liquid culture, shaking culture using a test tube or flask is preferred. When culturing in large quantities, it is preferable to culture with aeration and agitation as in the case of other fermentation products.
  • the composition of the medium used for the preculture and the medium used for the production culture may be the same, or may be changed if necessary.
  • the culture conditions can be appropriately changed within the range in which the lactic acid bacteria according to the present invention grow, but the culture is usually carried out at 15 to 45 ° C., preferably 25 to 37 ° C. under aerobic conditions.
  • the culture time varies depending on the culture conditions and the culture volume, but is usually about 1 day to 1 week.
  • lactic acid bacteria fermentation broth As the “processed product of dead cells of lactic acid bacteria” used in the present invention, for example, a lactic acid bacteria fermentation solution can be used.
  • the content of the lactic acid bacteria fermentation broth in the composition is not particularly limited, but for example 0.1 wt% to 100 wt% 0.1 wt% to 10 wt%, 0.5 wt% to 7.5 wt%, 1.0 wt% to 5.0 wt%, 1.0 wt% to 2.5 wt%, 0.1 wt% It can be contained in an amount of 20% to 20%, 20% to 40%, 40% to 60%, 60% to 80%, 80% to 100% by weight.
  • Examples of the lactic acid fermentation broth include the following.
  • Lactobacillus / pear juice fermented liquid Fermentage pear B (manufactured by Ichimaru Falcos) Lactobacillus / wasabi root fermentation extract: ACB Wasabi Extract SF (manufactured by Active Concepts LLC)
  • composition of the present invention includes at least a killed cell of lactic acid bacteria and / or a processed product of a killed cell of lactic acid bacteria according to the present invention, and any one or more of the following preventive effect, inhibitory effect, mitigating effect, and improving effect. Have a promoting effect, a mitigating effect, and / or a therapeutic effect.
  • composition of the present invention known food ingredients, functional food ingredients, pharmaceutical ingredients, cosmetic ingredients and the like can be blended as long as the effects of the present invention are not impaired.
  • zeolite, sericite (mica), Bacillus natto ⁇ viable bacteria (body), dead bacteria (body) may be used, and Bacillus natto powder is preferred.
  • dead cells of Bacillus natto include processed products of Bacillus natto, fermented natto, dried natto fermentation, dried natto broth (extracted natto extract) and mixtures thereof It is.
  • the composition of the present invention includes, for example, natto sterilized powder (nattokinase), enterococcus faecium sterilized powder, ascorbic acid, zinc oxide, titanium oxide, glyceryl stearate, N-acetylglucosamine, niacinamide, hydrolyzed collagen, adenosine, It can be set as the composition containing arbutin, kojic acid, allantoin, and water. The effect can be further enhanced by adding zeolite, sericite, natto, yeast and / or plant fermenting enzyme to the composition of the present invention.
  • zeolite, sericite, natto, yeast and / or plant fermenting enzyme to the composition of the present invention.
  • dead cells of Bacillus natto natto kinase or fermented Bacillus (INCI) can be used.
  • the mixing ratio of lactic acid bacteria to dead cells or processed products thereof is not particularly limited, but dead cells of lactic acid bacteria or processed products thereof: dead cells of Bacillus natto May be 0.1 to 2.5: 0.005 to 1.00, 0.5 to 20: 0.5 to 25, preferably 1: 0.01 to 0.75, 0.5 to 1.5: 0.01 to 0.75, 1.0 to 15: 1.0 to 20, or 2.0 to 12: 2.0 to 17.5, more preferably 1: 0.2 to 0 0.5, 0.75 to 1.25: 0.15 to 0.60, 2.5 to 10: 3.5 to 15, or 5.0 to 10: 5.0 to 15.
  • the composition of the present invention contains a lactic acid bacteria fermented liquid as a processed product of dead bacteria of lactic acid bacteria, and contains a natto bacterial dead cell as natto bacteria, the lactic acid bacteria fermented liquid in the composition and dead bacteria of natto bacteria
  • the total body content is not particularly limited. For example, 1.0% to 20% by weight, 3.5% to 15% by weight, 3.5% to 12.5% by weight, 3.5% by weight It can be contained up to 11% by weight.
  • the blending ratio of both is not particularly limited, but zeolite: sericite is preferably 0.51 to 0.99: 0.01 to 0.49 or 10 to 1000. : 1, more preferably 0.55 to 0.75: 0.25 to 0.45 or 50 to 500: 1.
  • zeolite: sericite is preferably 0.51 to 0.99: 0.01 to 0.49 or 10 to 1000. : 1, more preferably 0.55 to 0.75: 0.25 to 0.45 or 50 to 500: 1.
  • contamination of skin can be removed and the state of skin can be made favorable.
  • the composition of the present invention includes, for example, natto sterilized powder (nattokinase), enterococcus faecium sterilized powder, ascorbic acid, zinc oxide, titanium oxide, glyceryl stearate, N-acetylglucosamine, niacinamide, hydrolyzed collagen, adenosine, It can be set as the composition containing arbutin, kojic acid, allantoin, and water.
  • composition of the present invention is not particularly limited, but preferably any one or more selected from the following group (A), any one or more selected from the group (A) and (B), any one or more selected from the group of (A) and (C), or any one or more selected from the group of (A), (B) and (C).
  • the blending ratio of each component is not particularly limited, but when (A), (B) and (C) are included, preferably (A) :( B) :( C) is 0.5 to 1.5: 0. 01 to 0.75: 0.1 to 1.5, more preferably 0.75 to 1.25: 0.15 to 0.60: 0.1 to 1.25.
  • a combination of dead cells of Enterococcus faecalis, dead cells of Enterococcus faecium, zeolite, sericite and dead cells of Bacillus natto is particularly preferred.
  • the mixing ratio of Enterococcus faecalis dead cells and Enterococcus faecium dead cells is not particularly limited, but Enterococcus faecalis dead cells: Enterococcus faecium dead cells, for example, 0.01 to 0.99: 0 .01 to 0.99, 0.25 to 0.65: 0.35 to 0.75, 0.35 to 0.55: 0.45 to 0.65, preferably 0.35 to 0.75: 0 .25 to 0.65, more preferably 0.45 to 0.65: 0.35 to 0.55.
  • the feeling of use changes depending on the ratio of dead cells of Enterococcus faecalis and dead cells of Enterococcus faecium.
  • the odor of lactic acid bacteria is strong or slightly strong, and if it is less, the odor of lactic acid bacteria is weak or odorless.
  • the mixing ratio of each component is not particularly limited, but when (A) and (C) are included, (A) :( C) is 0.1 to 2.5: 0.005 to 1.00, 0.5 to 20: 0.5 to 25, preferably 0.5 to 1.5: 0.01 to 0.75, 1.0 to 15: 1.0 to 20, or 2.0 to 12: 2. 0.0-17.5, more preferably 0.75-1.25: 0.15-0.60, 2.5-10: 3.5-15 or 5.0-10: 5.0- 15.
  • Enterococcus faecalis dead cells Enterococcus faecalis dead cells, Enterococcus faecium dead cells and combinations of dead Bacillus natto, Enterococcus faecalis dead cells and Bacillus natto dead cells, or Enterococcus faecium dead cells
  • a combination of dead cells of Enterococcus faecalis, a combination of dead cells of Enterococcus faecium and dead cells of Bacillus natto, or a dead cell of Enterococcus faecium and Bacillus natto A combination of dead cells is more preferred.
  • the mixing ratio of Enterococcus faecalis dead cells and Enterococcus faecium dead cells is not particularly limited, but Enterococcus faecalis dead cells: Enterococcus faecium dead cells, for example, 0.01 to 0.99: 0 .01 to 0.99, 0.25 to 0.65: 0.35 to 0.75, 0.35 to 0.55: 0.45 to 0.65, or 0.05 to 15: 0.05 to 15 , Preferably 0.35-0.75: 0.25-0.65 or 0.1-10: 0.1-10, more preferably 0.45-0.65: 0.35-0.55 or 1.0 to 5.0: 1.0 to 5.0.
  • the mixing ratio of dead cells of Enterococcus faecalis and dead cells of Bacillus natto is not particularly limited, but dead cells of Enterococcus faecalis: dead cells of Bacillus natto, for example, 0.05 to 15: 0.5 to 20 Or 0.1 to 10: 1.0 to 15, preferably 0.1 to 5.0: 2.5 to 10, more preferably 1.0 to 5.0: 2.5 to 10. 0.1-2.5: 2.5-10, 0.1-2.0: 2.5-10, 0.1-1.5: 2.5-10 or 0.1-1.0 : 2.5-10.
  • the mixing ratio of the dead cells of Enterococcus faecium and the dead cells of Bacillus natto is not particularly limited, but the dead cell of Enterococcus faecium: dead cells of Bacillus natto, for example, 0.05 to 15: 0.5 to 20 Or 0.1 to 10: 1.0 to 15, preferably 0.1 to 5.0: 2.5 to 10, more preferably 1.0 to 5.0: 2.5 to 10. 0.1-4.0: 2.5-10, 0.1-3.0: 2.5-10, 0.1-2.5: 2.5-10, 0.1-2.0 : 2.5 to 10, 0.1 to 1.5: 2.5 to 10, or 0.1 to 1.0: 2.5 to 10.
  • compositions containing dead cells of Enterococcus faecalis, dead cells of Enterococcus faecium, zeolite, sericite, and dead cells of Bacillus natto include the compositions shown in Table 1 below.
  • each numerical value indicates a weight (g) per 100 g of the composition.
  • the daily intake of mammals is not particularly limited as a dry powder of dead cells. 3000 mg, about 0.1-10 mg, about 10-50 mg, about 50-100 mg, about 100-500 mg, about 500-1000 mg, preferably about 0.1-2000 mg, more preferably 1.0-100 mg, further Preferably, it is 2.0 to 50 mg.
  • the composition of the present invention may be mixed with cosmetics at the time of production or may be added to a finished product.
  • the cosmetic product in the present invention is not particularly limited, but for example, lotion, milky lotion, beauty cream, beauty lotion, pack, lipstick, foundation, cleansing, all-in-one cream, cleansing liquid, mist lotion, moisturizing beauty lotion, high moisturizing beauty. Examples thereof include liquid, hair wax, hair water, nail polish, eye shadow and the like.
  • the cosmetic additive composition of the present invention may contain a lactobacillus / pear juice fermented liquid (LACTOBACILLUS / PEAR JUICE FERMENT FILTRATE) as a processed product of dead lactic acid bacteria.
  • the cosmetic additive composition of the present invention can obtain a whitening effect by including a lactobacillus / pear juice fermented liquid.
  • the cosmetic additive composition of the present invention can contain Enterococcus faecalis (Fecaris RN8 strain) and / or Enterococcus faecium (BIO strain) as a treated product of dead lactic acid bacteria.
  • the cosmetic additive composition of the present invention contains Enterococcus faecalis (Fecaris RN8 strain) and / or Enterococcus faecium (BIO strain) to improve skin tension, improve spots, improve wrinkles, improve dullness, Reduction and / or tightening of pores, improvement of acne and / or breakout, improvement of skin, increase of skin moisture, reduction of skin age, improvement of hair quality, reduction of stomatitis, reduction of periodontal disease, reduction of bad breath, burns Promotion of recovery, reduction of skin itch, improvement of constipation, improvement of diarrhea, improvement of body odor, improvement of halitosis, stabilization of mind, improvement of allergy and / or atopy, improvement of diarrhea, improvement of constipation and / or bowel regulation, and / or reduction of stomach circumference
  • Enterococcus faecalis Fecaris RN8 strain
  • BIO strain Enterococcus faecium
  • composition of the present invention may be mixed with daily necessities at the time of production or may be added to a finished product.
  • Life products in the present invention are not particularly limited, for example, soap, body soap, bath agent, delicate zone soap, delicate zone soap, shaving cream, shaving gel, dishwashing detergent, shampoo, conditioner (rinse), toothpaste, Examples include laundry detergents, softeners, fragrances, masks, bedding covers and the like.
  • the composition for adding daily necessities of the present invention can contain Enterococcus faecalis (Fecaris RN8 strain) and / or Enterococcus faecium (BIO strain) as a treated product of dead lactic acid bacteria.
  • composition for adding daily necessities of the present invention contains Enterococcus faecalis (Fecaris RN8 strain) and / or Enterococcus faecium (BIO strain), thereby improving skin tension, improving spots, improving wrinkles, and improving dullness.
  • the composition of the present invention may be mixed with a drug at the time of manufacture, may be added to a finished product, or may be used together when the drug is used (during intake or application).
  • the drug in the present invention is not particularly limited.
  • anti-itch cream eczema improving cream, rough skin cream (ointment), burn ointment, poultice, analgesic sheet, constipation improving agent, diarrhea improving agent, mouthwash, mouthwash And toothpaste, sunscreen, antiperspirant and the like.
  • composition for drug addition of the present invention can contain Enterococcus faecalis (Fecaris RN8 strain) and / or Enterococcus faecium (BIO strain) as a treated product of dead lactic acid bacteria.
  • Enterococcus faecalis Fecaris RN8 strain
  • BIO strain Enterococcus faecium
  • the composition for drug addition of the present invention contains Enterococcus faecalis (Fecaris RN8 strain) and / or Enterococcus faecium (BIO strain) to improve skin tension, improve spots, improve wrinkles, improve dullness, Reduction and / or tightening of pores, improvement of acne and / or breakout, improvement of skin, increase of skin moisture, reduction of skin age, improvement of hair quality, reduction of stomatitis, reduction of periodontal disease, reduction of bad breath, burns Promotion of recovery, reduction of skin itch, improvement of constipation, improvement of diarrhea, improvement of body odor, improvement of halitosis, stabilization of mind, improvement of allergy and / or atopy, improvement of diarrhea, improvement of constipation and / or bowel regulation, and / or reduction of stomach circumference
  • Preventive effect suppressive effect, mitigating effect, improving effect, promoting effect, mitigating effect, and / or therapeutic effect.
  • the composition of the present invention may be mixed with known foods (including functional foods, health foods, etc.) at the time of production, or may be added to the foods at the time of consumption so that they can be taken together.
  • the food in the present invention is not particularly limited, for example, beverages such as soft drinks (for example, water, juice, smoothie, coffee, tea), natto, yogurt, cheese, etc.
  • beverages such as soft drinks (for example, water, juice, smoothie, coffee, tea), natto, yogurt, cheese, etc.
  • fermented foods, semi-solid foods such as dietary supplements, solid foods such as confectionery (eg, candy, snack confectionery, gum, baked confectionery, fresh confectionery), powdered foods such as dried vegetable powder, dried cereal powder, and dried seaweed powder can do.
  • composition for food addition of the present invention can contain Enterococcus faecalis (Fecaris RN8 strain) and / or Enterococcus faecium (BIO strain) as a treated product of dead lactic acid bacteria.
  • Enterococcus faecalis Fecaris RN8 strain
  • BIO strain Enterococcus faecium
  • the composition for food addition of the present invention contains Enterococcus faecalis (Fecaris RN8 strain) and / or Enterococcus faecium (BIO strain) to improve skin tension, improve spots, improve wrinkles, improve dullness, Reduction and / or tightening of pores, improvement of acne and / or pimples, improvement of skin, increase of skin moisture, reduction of skin age, improvement of hair quality, reduction of stomatitis, reduction of periodontal disease, reduction of bad breath, burns Promotion of recovery, reduction of skin itchiness, improvement of constipation, improvement of diarrhea, improvement of body odor, improvement of halitosis, stabilization of mind, improvement of allergy and / or atopy, improvement of diarrhea, improvement of constipation and / or bowel regulation and / or reduction of stomach circumference Can be obtained.
  • Enterococcus faecalis Fecaris RN8 strain
  • BIO strain Enterococcus faecium
  • the present invention is also directed to any one or more of the following methods characterized by using dead cells of lactic acid bacteria or processed products thereof.
  • Skin tension improvement method (2) Blemish improvement method (3) Wrinkle improvement method (4) Dullness improvement method (5) Pore reduction and / or tightening method (6) Acne and / or pimples Improvement method (7) Skin improvement method (8) Skin moisture increase method (9) Skin age reduction method (10) Hair quality improvement method (11) Stomatitis reduction method (12) Periodontal disease reduction method ( 13) Bad breath reduction method (14) Burn recovery promotion method (15) Skin itch reduction method (16) Constipation improvement method (17) Diarrhea improvement method (18) Body odor improvement (19) Bad breath improvement (20) Mental stabilization (21 ) Improvement of allergy and / or atopy (22) Improvement of diarrhea, improvement of constipation and / or improvement of bowel movement (23) Reduction of circumference of the stomach Cats, dogs, etc.).
  • the method of treatment is not particularly limited.
  • administration for example, oral administration
  • application skin, especially face, hand, body, cheek or nose
  • spray skin, particularly face, hand, body, cheek or nose
  • the treatment frequency is not particularly limited. For example, once to 10 times a day, 1 to 5 times a day, 1 to 3 times a day, once to 2 to 5 days, 1 week to 4 times Can be processed once to 10 times a week.
  • the treatment period is not particularly limited, and may be, for example, 1 day or more, 1 to 5 days, 1 to 4 weeks, 1 month to 6 months, 6 months to 1 year, 1 year or more.
  • the treatment amount is not particularly limited as a dry powder of dead cells in terms of daily intake, but for example, about 0.01 to 3000 mg / day, about 0.1 to 10 mg / day, about 10 to 50 mg / day, about 50-100 mg / day, about 100-500 mg / day, about 500-1000 mg / day, preferably about 0.1-2000 mg / day, more preferably 1.0-100 mg / day, further Preferably, it is 2.0 to 50 mg / day.
  • Lactic acid killed cells contained in the composition of the present invention used in the following examples were obtained by commercially available lactic acid killed cells or the following known methods for preparing lactic acid killed cells.
  • Enterococcus faecalis Enterococcus faecalis
  • Enterococcus faecium Enterococcus faecium
  • BIO strain Bifidobacterium longum Commercial product Lactbacillus casei subsp.casei (Lactobacillus casei subspecies casei): Commercial product Lactobacillus paracasei: Commercial product Lactobacillus crispatus: Commercial product
  • Preparation of dry powder of lactic acid dead cells A preculture solution obtained by culturing the above lactic acid strain in a known medium at 37 ° C. for 24 hours was further inoculated into a liquid medium, and cultured at 37 ° C. for 1 day while adjusting pH. After completion of the culture, the cells were separated and collected with a centrifuge. This operation was repeated several times as necessary to wash the cells. Next, the washed cells are suspended in distilled water, sterilized at about 100 ° C. for 30 minutes, and then dried using a spray dryer to obtain a heat-treated cell powder (dried lactic acid cell powder). It was.
  • composition of the present invention prepared in Example 1 (dry powder of each lactic acid bacteria dead cell, dry powder containing lactic acid dead cells and natto bacteria, dry powder containing lactic acid dead cells, zeolite and sericite, or lactic acid
  • the effect of the composition of the present invention was confirmed by hearing of each subject using dry cells containing dead cells, zeolite, sericite and natto. The method for confirming the effect is shown in FIGS.
  • the skin age (measuring device: Super Skin Checker, Ito Super Short Wave Co., Ltd.) of a woman (34 to 57 years old) who ingested Enterococcus faecalis dead cells or Enterococcus faecium dead cells among each subject. It was measured. Specifically, the skin age before ingesting the composition of the present invention on the skin was compared with the skin age after ingestion for about 1 month. By taking the composition of the present invention, it was confirmed that the skin age decreased from -8 years to -19 years. That is, the composition of the present invention has an effect of reducing skin age.
  • periodontal disease was improved the next day after the intake.
  • periodontal disease was further improved by ingesting for several days to one week.
  • O Reduction effect of bad breath The subjects suffering from bad breath who ingested dead Enterococcus faecalis cells or Enterococcus faecium dead cells were confirmed to have improved bad breath than toothpaste alone.
  • composition of this invention confirmed that the said effect was so high that there was much content of a lactic-acid-bacteria dead cell. Furthermore, the composition of the present invention has a higher effect by containing Bacillus natto and / or zeolite and sericite (for example, when zeolite and sericite are contained, higher skin whitening and moisturizing effect). , Dullness reduction effect, pore dirt removal effect, pore tightening effect). In addition, it was confirmed that when the composition of the present invention was contained in commercial cosmetics and daily necessities, the above-mentioned effects were obtained without inhibiting the efficacy of the commercial cosmetics and daily necessities.
  • Enterococcus faecalis dead cell and Enterococcus faecium dead cell confirmed the excellent effect compared with four types of lactic acid dead cells (Bifidobacterium longum, Lactbacillus casei subsp.casei, Lactobacillusparacasei, Lactobacillus crispatus).
  • composition of this invention confirmed that the said effect was so high that there was much content of a lactic-acid-bacteria dead cell. Furthermore, it was confirmed that the composition of the present invention has a higher effect by containing natto bacteria and / or zeolite and sericite (for example, an even better diarrhea improving effect by containing natto bacteria). In addition, when the composition of the present invention was administered in combination with a commercially available drug, it was confirmed that the composition had the above-described effect without inhibiting the efficacy of the commercially available drug.
  • Food candy ⁇ Three types of commercially available candy with 10 mg, 50 mg, or 100 mg of dried powder containing each dead lactic acid bacteria or 10 mg, 50 mg, or 100 mg dry powder containing lactic acid dead bacteria and natto bacteria licked to each subject a day received. And we interviewed the effect of licking the heel.
  • Food confectionery snack Three types of commercially available snack snacks (potato chips) each day with 10mg, 50mg or 100mg of dry powder containing each lactic acid bacteria dead powder or dry powder containing lactic acid dead bacteria and natto Each subject had a bag eaten. And we interviewed the effect of eating this snack.
  • composition of the present invention alone
  • Each subject took a composition containing 10 mg, 50 mg, or 100 mg of each dry powder of lactic acid bacteria or dry powder containing lactic acid dead bacteria and natto bacteria per capsule (or 1 tablet). And it interviewed about the effect after eating this composition.
  • diarrhea could be improved in 30 minutes to 1 hour when enterococcus faecalis dead cells + natto bacteria or enterococcus faecium dead cells + natto bacteria were ingested after feeling the symptoms of diarrhea. .
  • diarrhea did not occur when a person with diarrhea was ingested before or before a meal.
  • the number of diarrhea decreased or constipation was reduced by taking for several days to one week.
  • a subject suffering from bad breath who ingested dead cells of Enterococcus faecalis or Enterococcusfaecium was confirmed to have improved bad breath. More specifically, it was confirmed that bad breath was reduced the next day after the intake. It was confirmed that halitosis was further reduced by ingesting for several days to one week. More specifically, of each subject, the bad breath (a breath odor measuring device: Breath Checker, manufactured by Tanita) of a woman (34 to 57 years old) who took Enterococcus faecalis dead cells or Enterococcus faecium dead cells was measured. Specifically, the bad breath before ingestion of the composition of the present invention was compared with the bad breath after ingestion for about 1 month. It was confirmed that the bad breath level of all subjects was lowered by ingestion of the composition of the present invention.
  • Breath Checker manufactured by Tanita
  • the waist circumference was measured of a woman (34 to 57 years old) who took Enterococcus faecalis dead cells or Enterococcus faecium dead cells. Specifically, before taking the composition of the present invention on the skin. The abdominal circumference was compared with the abdominal circumference after ingestion for about 1 month, and a decrease in the abdominal circumference of -5.0 cm to -9.0 cm was confirmed by ingestion of the composition of the present invention. That is, the composition of the present invention has an effect of reducing stomach circumference.
  • composition of this invention confirmed that the said effect was so high that there was much content of a lactic-acid-bacteria dead cell. Furthermore, it has been confirmed that the composition of the present invention is more effective (eg, improves diarrhea) by containing Bacillus natto. In addition, when the composition of the present invention was added to a commercially available food, it was confirmed that the composition had the above-described effect without inhibiting the efficacy of the commercially available food.
  • Enterococcus faecalis dead cell and Enterococcus faecium dead cell confirmed the excellent effect compared with four types of lactic acid dead cells (Bifidobacterium longum, Lactbacillus casei subsp.casei, Lactobacillusparacasei, Lactobacillus crispatus).
  • composition containing dead lactic acid bacteria or a processed product thereof according to the present invention can provide various uses.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Birds (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Confectionery (AREA)
  • Preparation Of Fruits And Vegetables (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Cosmetics (AREA)

Abstract

L'invention fournit une nouvelle application pour cellules mortes de bactéries d'acide lactique. Ainsi, l'invention concerne une nouvelle application pour cellules mortes de bactéries d'acide lactique basée sur une sélection optimale de bactéries d'acide lactique, et en outre sur une sélection optimale d'additifs.
PCT/JP2018/006832 2017-02-24 2018-02-24 Composition comprenant des cellules mortes de bactéries d'acide lactique ou une substance traitée de celles-ci, et article cosmétique, produit de consommation courante, médicament ainsi qu'aliment contenant cette composition WO2018155660A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019501847A JPWO2018155660A1 (ja) 2017-02-24 2018-02-24 乳酸菌の死菌体又はその処理物を含有する組成物並びに該組成物を含む化粧品、生活用品、薬剤又は食品

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2017032972 2017-02-24
JP2017-032972 2017-02-24
JP2017032973 2017-02-24
JP2017-032973 2017-02-24

Publications (1)

Publication Number Publication Date
WO2018155660A1 true WO2018155660A1 (fr) 2018-08-30

Family

ID=63253888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/006832 WO2018155660A1 (fr) 2017-02-24 2018-02-24 Composition comprenant des cellules mortes de bactéries d'acide lactique ou une substance traitée de celles-ci, et article cosmétique, produit de consommation courante, médicament ainsi qu'aliment contenant cette composition

Country Status (2)

Country Link
JP (1) JPWO2018155660A1 (fr)
WO (1) WO2018155660A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020004580A1 (fr) * 2018-06-28 2020-01-02 一丸ファルコス株式会社 Agent empêchant la production d'odeur corporelle contenant une bactérie d'acide lactique
JP2020079236A (ja) * 2018-11-12 2020-05-28 有限会社バイオ研 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材
JP2020105100A (ja) * 2018-12-27 2020-07-09 ロート製薬株式会社 ヒアルロン酸産生促進用組成物及びヒアルロン酸産生促進方法
JP2020197411A (ja) * 2019-05-31 2020-12-10 株式会社ミルボン 評価方法、頭皮毛髪化粧料の選定方法、評価支援ツール、有効成分の候補物質のスクリーニング方法、頭皮毛髪化粧料の製造方法、及び、被評価者を選別するスクリーニング方法
CN112481148A (zh) * 2019-08-22 2021-03-12 丰华生物科技股份有限公司 用于美白功效的含乳酸菌发酵物的组合物及其用途
JP7412687B2 (ja) 2019-11-07 2024-01-15 ユニチカトレーディング株式会社 機能性織編物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006347925A (ja) * 2005-06-14 2006-12-28 Kyoei Kagaku Kogyo Kk 植物発酵物及びこれを含む化粧料
JP2007099625A (ja) * 2005-09-30 2007-04-19 Ryukyu Bio Resource Kaihatsu:Kk 皮膚線維芽細胞増殖促進剤
JP2010006801A (ja) * 2008-05-30 2010-01-14 Bio Medical Research Group:Kk 乳酸菌配合物及びその製造方法
JP2010173991A (ja) * 2009-01-30 2010-08-12 Kouai Kagaku Co Ltd 皮膚外用剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006347925A (ja) * 2005-06-14 2006-12-28 Kyoei Kagaku Kogyo Kk 植物発酵物及びこれを含む化粧料
JP2007099625A (ja) * 2005-09-30 2007-04-19 Ryukyu Bio Resource Kaihatsu:Kk 皮膚線維芽細胞増殖促進剤
JP2010006801A (ja) * 2008-05-30 2010-01-14 Bio Medical Research Group:Kk 乳酸菌配合物及びその製造方法
JP2010173991A (ja) * 2009-01-30 2010-08-12 Kouai Kagaku Co Ltd 皮膚外用剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
32 SCCJ 5 FRAGRANCE JOURNAL, November 2007 (2007-11-01), pages 92 - 96 *
MASAKI, HITOSHI: "Lysophosphatidic acid as materials for epidermis care", FRAGRANCE JOURNAL, May 2009 (2009-05-01), pages 31 - 34 *
NEWS & NEWS, FRAGRANCE JOURNAL, September 2013 (2013-09-01), pages 4 - 9 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020004580A1 (fr) * 2018-06-28 2020-01-02 一丸ファルコス株式会社 Agent empêchant la production d'odeur corporelle contenant une bactérie d'acide lactique
JPWO2020004580A1 (ja) * 2018-06-28 2021-08-05 一丸ファルコス株式会社 乳酸菌を含有する体臭発生抑制剤
JP2020079236A (ja) * 2018-11-12 2020-05-28 有限会社バイオ研 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材
JP7045671B2 (ja) 2018-11-12 2022-04-01 有限会社バイオ研 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材
JP2020105100A (ja) * 2018-12-27 2020-07-09 ロート製薬株式会社 ヒアルロン酸産生促進用組成物及びヒアルロン酸産生促進方法
JP2020197411A (ja) * 2019-05-31 2020-12-10 株式会社ミルボン 評価方法、頭皮毛髪化粧料の選定方法、評価支援ツール、有効成分の候補物質のスクリーニング方法、頭皮毛髪化粧料の製造方法、及び、被評価者を選別するスクリーニング方法
JP7337551B2 (ja) 2019-05-31 2023-09-04 株式会社ミルボン 評価方法、頭皮毛髪化粧料の選定方法、評価支援ツール、有効成分の候補物質のスクリーニング方法、頭皮毛髪化粧料の製造方法、及び、被評価者を選別するスクリーニング方法
CN112481148A (zh) * 2019-08-22 2021-03-12 丰华生物科技股份有限公司 用于美白功效的含乳酸菌发酵物的组合物及其用途
JP7412687B2 (ja) 2019-11-07 2024-01-15 ユニチカトレーディング株式会社 機能性織編物

Also Published As

Publication number Publication date
JPWO2018155660A1 (ja) 2019-11-07

Similar Documents

Publication Publication Date Title
WO2018155660A1 (fr) Composition comprenant des cellules mortes de bactéries d'acide lactique ou une substance traitée de celles-ci, et article cosmétique, produit de consommation courante, médicament ainsi qu'aliment contenant cette composition
JP5791009B2 (ja) 乳酸菌およびそれらを用いた飲食物又は化粧品
TWI786343B (zh) 用於美白功效之含乳酸菌發酵物之組合物及其用途
CN104277998A (zh) 用于预防和/或治疗口腔恶臭的用途和方法
JP2008179601A (ja) ラクトバチルス属菌を含む美容組成物
KR20060135016A (ko) 유카 추출물, 퀼라야 추출물 및 유산균을 포함하는 조성물및 상기 조성물을 함유하는 음식물
TWI689585B (zh) 新穎乳酸菌株及包含新穎乳酸菌株之免疫賦活劑
JP5270680B2 (ja) 葉酸が混入された大豆発酵高分子物質及びこれを含む組成物
KR102040972B1 (ko) 피부 노화 방지 또는 주름 개선 활성이 있는 신규한 비피도박테리움 락티스(Bifidobacterium lactis) UBC-U04 및 이를 이용한 조성물
KR20160110829A (ko) 피부 미백 효능을 가지는 락토바실러스 파라카제이 hy7301 우유 발효물 및 이를 유효성분으로 함유하는 제품
TWI807545B (zh) 製造囊化益生菌的方法、囊化益生菌、包含其之食品或功能性健康食品、醫藥組合物或藥劑及化妝品組合物
KR102311097B1 (ko) 초유의 호기성 발효산물
KR101409760B1 (ko) 피부주름 개선 효능을 가지는 우뭇가사리와 엉겅퀴 추출 복합물의 유산균 발효물 및 이를 유효성분으로 함유하는 제품
JP2005013211A (ja) 乳酸菌含有食品組成物
CN107530382B (zh) 防龋剂和防龋组合物
JP2000245391A (ja) 健康食品
CN102742654B (zh) 一种养颜美容益生菌羊奶片及其制备方法
KR102332021B1 (ko) A2 베타 카제인 단백질이 포함된 배지 조성물을 이용한 아미노바이오틱스의 제조방법 및 이를 통해 제조한 아미노바이오틱스
KR102254553B1 (ko) 모발 성장 촉진 효능을 가지는 락토바실러스 파라카제이 hy7015 및 이를 유효성분으로 함유하는 모발 성장 촉진을 위한 조성물
JP2019119689A (ja) 皮膚状態改善剤
RU2413761C1 (ru) Lactobacillus fermentum Ess-1, DSM17851, И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ И/ИЛИ ПРОФИЛАКТИКИ КАНДИДОЗА И ИНФЕКЦИЙ МОЧЕВЫХ ПУТЕЙ
JP2022077034A (ja) ハマボウ抽出物、同ハマボウ抽出物を含有する化粧料及び機能性食品
CN114470005B (zh) 益生菌和透明质酸钠的组合物及其应用
JP2019218280A (ja) 入浴用組成物
TWI764356B (zh) 含乳酸菌菌株或其發酵物的抗老化組合物及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18756928

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019501847

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18756928

Country of ref document: EP

Kind code of ref document: A1